These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18513919)

  • 1. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome.
    Mylona E; Giannopoulou I; Diamantopoulou K; Bakarakos P; Nomikos A; Zervas A; Nakopoulou L
    Eur J Surg Oncol; 2009 Feb; 35(2):197-201. PubMed ID: 18513919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
    Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
    Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression and cross-talk of peroxisome proliferator-activated receptor γ and retinoid-X receptor α in urothelial carcinomas of the bladder.
    Petta E; Sotiropoulou-Bonikou G; Kourelis K; Melachrinou M; Bonikos DS
    J BUON; 2010; 15(4):740-5. PubMed ID: 21229639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
    Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
    Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer.
    Mavrommatis J; Mylona E; Gakiopoulou H; Stravodimos C; Zervas A; Giannopoulos A; Nakopoulou L
    Anticancer Res; 2005; 25(4):3109-16. PubMed ID: 16080574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
    Pancione M; Forte N; Sabatino L; Tomaselli E; Parente D; Febbraro A; Colantuoni V
    Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma.
    Nakamura Y; Suzuki T; Sugawara A; Arai Y; Sasano H
    Pathol Int; 2009 May; 59(5):288-93. PubMed ID: 19432669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
    Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
    Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta.
    Papadaki I; Mylona E; Giannopoulou I; Markaki S; Keramopoulos A; Nakopoulou L
    Histopathology; 2005 Jan; 46(1):37-42. PubMed ID: 15656884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
    Kristiansen G; Jacob J; Buckendahl AC; Grützmann R; Alldinger I; Sipos B; Klöppel G; Bahra M; Langrehr JM; Neuhaus P; Dietel M; Pilarsky C
    Clin Cancer Res; 2006 Nov; 12(21):6444-51. PubMed ID: 17085658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
    Yang CC; Chu KC; Yeh WM
    Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
    Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
    Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder.
    Mylona E; Zarogiannos A; Nomikos A; Giannopoulou I; Nikolaou I; Zervas A; Nakopoulou L
    APMIS; 2008 Jan; 116(1):59-65. PubMed ID: 18254781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.